H.C. Wainwright raised the firm’s price target on Palvella Therapeutics (PVLA) to $255 from $200 and keeps a Buy rating on the shares. Phase 3 SELVA data, with the mLM-IGA primary endpoint demonstrating a statistically significant 2.13-point mean change, is “a clear and decisive win,” says the analyst, who believes that the efficacy demonstrated in the SELVA trial will likely result in strong and continued uptake among patients if approved.

Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions

Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on PVLA:

Disclaimer & DisclosureReport an Issue

Palvella Reports Positive Phase 3 Data for QTORIN Gel

Palvella Reports Positive Phase 3 Data for QTORIN

Palvella Therapeutics’ qtorin meets primary endpoint in lymphatic malformations

Palvella Therapeutics (PVLA): Mechanistic Validation, Unmet Need, and Pivotal Trial Catalysts Underpin Buy Rating

Palvella Therapeutics management to meet virtually with Craig-Hallum